-
ABSL Medium Term Plan Regular Quarterly IDCW: NAV Today, Performance Review and Should You Invest?
- July 23, 2026
- Posted by: Neeraj Pandey
- Category: News
No Comments
ABSL Medium Term Plan Regular Quarterly IDCW NAV, latest returns and full review including risks and how to invest.
-
IndusInd Bank Share Price Target Raised to Rs 820 by JPMorgan, Which Keeps Its Underweight Rating
- July 23, 2026
- Posted by: Kunal Singla
- Category: News
IndusInd Bank share price target is raised to Rs 820 by JPMorgan, though the brokerage keeps its underweight rating. Check the Q1 beat, NIM trend and valuation view.
-
Abbott India vs Sanofi India Business Model: Which MNC Pharmaceuticals Wins
- July 23, 2026
- Posted by: Ankit Jaiswal
- Category: News
Abbott India vs Sanofi India business model compares diversified branded formulations across multiple therapeutic categories against concentrated diabetes care and consumer healthcare product portfolio to see which mnc pharmaceuticals has better business model.
-
ABSL Short Term Direct IDCW: NAV Today, Performance Review and Should You Invest?
- July 23, 2026
- Posted by: Neeraj Pandey
- Category: Mutual Funds
ABSL Short Term Direct IDCW NAV, latest returns and full review including risks and how to invest.
-
BSE Auto Index Rises 0.7 Percent as Hero MotoCorp, Bosch and Bajaj Auto Lead Sector Gainers
- July 23, 2026
- Posted by: Kunal Singla
- Category: News
BSE Auto index rises 0.7 percent today with Hero MotoCorp, Bosch and Bajaj Auto among the top gainers. Check the full list of auto stock movers and levels here.
-
Ajanta Pharma vs JB Chemicals Business Model: Which Domestic Branded Formulations Wins
- July 23, 2026
- Posted by: Ankit Jaiswal
- Category: News
Ajanta Pharma vs JB Chemicals business model compares concentrated ophthalmology therapeutic focus with meaningful export exposure against concentrated cardiac and gastro-intestinal therapeutic branded formulations to see which domestic branded formulations has better business model.
-
ABSL Low Duration Direct Weekly IDCW: NAV Today, Performance Review and Should You Invest?
- July 23, 2026
- Posted by: Neeraj Pandey
- Category: Mutual Funds
ABSL Low Duration Direct Weekly IDCW NAV, latest returns and full review including risks and how to invest.
-
Windlas Biotech vs Mankind Pharma Business Model: Which Branded and Contract Formulations Wins
- July 23, 2026
- Posted by: Ankit Jaiswal
- Category: News
Windlas Biotech vs Mankind Pharma business model compares concentrated domestic contract manufacturing for branded generics against scale-led domestic branded generics combined with consumer healthcare products to see which branded and contract formulations has better business model.
-
ABSL Money Manager Retail Daily IDCW: NAV Today, Performance Review and Should You Invest?
- July 23, 2026
- Posted by: Neeraj Pandey
- Category: Mutual Funds
ABSL Money Manager Retail Daily IDCW NAV, latest returns and full review including risks and how to invest.
-
Hero Motocorp Share Price Jumps 3.31 Percent, Its Biggest Rise in 11 Weeks
- July 23, 2026
- Posted by: Kunal Singla
- Category: News
Hero Motocorp share price jumps 3.31 percent today, its biggest single day rise in 11 weeks. Check CMP, 52 week range, market cap and volume trend here.